Navigation Links
Ampio Pharmaceuticals, Inc. States that its Policy is Not to Comment on Unusual Market Activity
Date:10/25/2013

GREENWOOD VILLAGE, Colo., Oct. 25, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it was contacted by the New York Stock Exchange in light of unusual market activity in the Company's common stock on Thursday, October 24, 2013. In accordance with the New York Stock Exchange's usual practice, the Company announced that its policy is not to comment on unusual market activity; however, the management did summarize significant milestones achieved over the past ten weeks including:

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

  • Positive results for Ampion in osteoarthritis of the knee clinical trial
  • $25 million financing
  • Positive summary data from Luoxis Diagnostics' study of traumatic brain injury patients and issuance of company's third US patent for its oxidation-reduction potential diagnostic platform
  • Positive results from Independent Panel Review of the interim analysis of the Optina trial for diabetic macular edema

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the completion, timing and size of the registered direct offering, as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
Email: rgiles@ampiopharma.com


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
2. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
3. Ampio Pharmaceuticals, Inc. Announces $25 Million Financing
4. Astellas to Host Executive Womens Day at 2013 TOUR Championship by Coca-Cola
5. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
6. Levine Leichtman Acquires Champion Manufacturing
7. Pro Athletes Team Up to Champion Gout Awareness
8. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
9. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
10. Ampio Pharmaceuticals to List on the NYSE MKT
11. Ampio Pharmaceuticals Provides Clinical Updates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Acute Myeloid Leukemia Drugs Price ... in the global Acute Myeloid Leukemia market. This research ... find out how the marketed products for Acute Myeloid Leukemia are ...
(Date:3/1/2017)... El mismo sistema se mostrará en el Congreso Europeo de Radiología (CER) ... ... The open MRI scanner - MROpen engineered and developed by Paramed in the ... Paramed ... primera en Gales. El escáner se localizará en el nuevo centro del European Scanning Centre ...
(Date:2/28/2017)... 2017 Persistence Market Research tables a ... market in a new publication named, "Dysphagia Management ... the name suggests, we have forecasted the global ... on the basis of the various market segments ... opportunities available to all the companies operating in ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... ... announce the release of its 2017 update to Compass, the popular online ... physician advisors. , Suitable for standardizing both new-hire on-boarding and annual competency-validation, ...
(Date:3/1/2017)... ... , ... Expert on international living and leading a healthy lifestyle, Alina Reyzelman, ... & Go app is the ultimate strategic compass that helps users to achieve goals ... people to work smarter, not harder, that's why Time & Go app provides tools ...
(Date:3/1/2017)... ... ... is Comfort for the Soul”: a loving account of a very special dog, the ... soul-healing comfort provided by God’s presence in the face of deep sorrow. “There is ... dog-loving medical professional whose work takes her to remote areas in the American Northwest, ...
(Date:3/1/2017)... ... ... to the Law of God”: a message about the revelation of God to our dark ... God” is the creation of published author Brent Chrishon, a former sales professional who left ... dedicated their lives to spreading God’s word both in the United States and abroad. , ...
(Date:2/28/2017)... ... February 28, 2017 , ... Answering strong demand for its medical ... will open a branch office in the Soma neighborhood in San Francisco on March ... factors, FDA regulatory and software systems architecture subject matter experts. , Orthogonal serves a ...
Breaking Medicine News(10 mins):